ByTrending Posts
Novartis Builds on a Track Record of Expansion…
Basel, Switzerland Novartis closed 2025 with sustained operational momentum, building on its transformation into a pure-play innovative medicines…
Regeneron to Present at 44th Annual J.P. Morgan…
TARRYTOWN, N.Y. – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it will webcast its presentation at the…
QALSODY® Shows Long-Term Benefits for SOD1-ALS Patients, Including…
Cambridge, Mass. Biogen Inc. (Nasdaq: BIIB) today announced that The Journal of the American Medical Association (JAMA) Neurology…
Can Jacobio Pharma and AstraZeneca Transform KRAS Cancer…
Shanghai/London Chinese biotech innovator Jacobio Pharma has entered a landmark global out-licensing agreement with AstraZeneca to advance its…
Is Samsung Biologics Set to Expand U.S. Operations…
Seoul/Washington, D.C. South Korea’s Samsung Biologics has announced its acquisition of its first U.S.-based drug production facility from…
Can TrumpRx and Pfizer’s Discount Deal Reshape Prescription…
Washington, D.C. The U.S. administration has announced the launch of TrumpRx, a federally operated digital platform designed to…
Is McRae Tech Setting a New Standard for…
McRae Tech has introduced Orchestral, a health-focused AI orchestrator data platform designed to support large-scale, governed use of…
Is Sanofi Strengthening Its Adult Vaccine Strategy with…
Paris, France Sanofi has taken a major step to strengthen its adult vaccines portfolio by announcing a $2.2…
Has Sanofi’s Dupixent Been Approved for Pediatric Asthma…
Tokyo, Japan – December 23, 2025 Sanofi and Regeneron have received regulatory approval in Japan for Dupixent (dupilumab)…
Trending Posts
Latest Stories
Are AI Healthcare Tools Raising Ethical and Access Concerns?
January 26, 2026 | AI in Healthcare | Ethics, Equity & Policy Recent commentary in…
Is “ChatGPT for Doctors” Driving OpenEvidence’s $12 B Valuation Surge?
January 26, 2026 | AI in Healthcare | Strategic Investment & Market Expansion OpenEvidence, the…
Can GSK’s New Leadership Translate into Multi-Franchise Growth in 2026?
Late January 2026 | Full-Year 2025 Earnings Preview | Vaccines, Immunology & Specialty Care GlaxoSmithKline…
Can Gilead Sustain Growth Beyond HIV and Hepatitis in 2026?
Late January 2026 | Full-Year 2025 Earnings Preview | Antivirals, Oncology & Emerging Therapies Gilead…
Gallery
